EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The evolving role of artificial intelligence in optimizing treatment and patient selection in diabetic macular edema

Dhanashree Ratra, Ramachandran Rajalakshmi, M Suchetha, Devanjali Relan, J S Deepikasri, Sundaramoorthy Sathishkumar, Aashna Ratra

Indian Journal of Ophthalmology · 2026-05 · 74 (5) · 690-697

DOI: 10.4103/ijo.ijo_3152_25 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Indian Journal of Ophthalmology, online erschienen am 29.04.2026. Verfasst von Dhanashree Ratra und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vitreoretinal Diseases, Sankara Nethralaya, Chennai, Tamil Nadu, India. Hauptthemen laut MEDLINE: Macular Edema, Diabetic Retinopathy, Artificial Intelligence, Patient Selection. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-vascular endothelial growth factor (anti-VEGF) therapy is the mainstay of management for diabetic macular edema (DME), but marked variability in response, high injection frequency, and cumulative treatment burden highlight the need for tools that can individualize treatment beyond protocol-driven regimens. Artificial intelligence (AI) offers a pathway toward more individualized risk stratification and prognostic support primarily by capturing statistical associations rather than biological mechanisms. Deep learning systems have achieved great accuracy in detecting diabetic retinopathy (DR) and DME. Several autonomous DR/DME screening solutions are in clinical use. Recent advances have applied supervised machine learning, convolutional neural networks, generative adversarial networks, and ensemble methods to multimodal data from fundus images, baseline and follow-up optical coherence tomography (OCT), along with clinical and biochemical data, to classify likely responders and non-responders. These models automatically quantify and track imaging biomarkers to accurately predict central subfield thickness and vision outcomes after loading doses, and estimate future injection burden. AI-driven decision-support tools analyze vast amounts of patient data, treatment histories, and integrate multimodal data, including fundus images, OCT images, and systemic data to provide recommendations for optimal treatment and follow-up, tailored to each individual profile. The AI systems can potentially generate individualized risk and response profiles that can support decisions on initiating therapy, choosing between agents, tailoring treat-and-extend intervals, and timing switches to steroids or combination strategies. However, issues of generalizability, transparency, workflow integration, and ethical deployment need to be systematically addressed. AI-enabled decision support for patient selection and treatment response prediction is poised to become an integral component of anti-VEGF therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macular EdemaDiabetic RetinopathyArtificial IntelligencePatient SelectionAngiogenesis InhibitorsHumansTomography, Optical CoherenceVascular Endothelial Growth Factor AIntravitreal InjectionsConvolutional Neural Networks

Stichwörter der Autor:innen

Anti-VEGF therapyartificial intelligenceconvolutional neural networkdeep learningdiabetic macular edema

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Vitreoretinal Diseases, Sankara Nethralaya, Chennai, Tamil Nadu, India.
  • Department of Ophthalmology, Dr. Mohan's Diabetes Specialities Centre and Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India.
  • Centre for Healthcare Advancements, Innovation and Research, Vellore Institute of Technology, Chennai, Tamil Nadu, India.
  • CSE Department, BML Munjal University, Gurugram, Haryana, India.
  • Department of Visual Neuroscience, Sorbonne University, Paris, France.
  • Department of Ophthalmology, Stanley Medical College, Chennai, Tamil Nadu, India.

Zitieren

APA

Ratra, D., Rajalakshmi, R., Suchetha, M., Relan, D., Deepikasri, J. S., Sathishkumar, S., & Ratra, A. (2026). The evolving role of artificial intelligence in optimizing treatment and patient selection in diabetic macular edema. Indian Journal of Ophthalmology, 74(5), 690-697. https://doi.org/10.4103/ijo.ijo_3152_25

Vancouver

Ratra D, Rajalakshmi R, Suchetha M, Relan D, Deepikasri JS, Sathishkumar S, et al. The evolving role of artificial intelligence in optimizing treatment and patient selection in diabetic macular edema. Indian Journal of Ophthalmology. 2026;74(5):690-697. doi:10.4103/ijo.ijo_3152_25

BibTeX
@article{Ratra2026,
  author = {Ratra, Dhanashree and Rajalakshmi, Ramachandran and Suchetha, M and Relan, Devanjali and Deepikasri, J S and Sathishkumar, Sundaramoorthy and Ratra, Aashna},
  title = {The evolving role of artificial intelligence in optimizing treatment and patient selection in diabetic macular edema},
  journal = {Indian Journal of Ophthalmology},
  year = {2026},
  volume = {74},
  number = {5},
  pages = {690--697},
  doi = {10.4103/ijo.ijo_3152_25}
}
Kostenlos starten →